CRISPR Therapeutics AG Stock News

Chinese-based generative artificial intelligence (AI) start-up DeepSeek is dominating conversations in technology and stock markets due to its performance, reportedly rivaling dominant players such as OpenAI's ChatGPT.

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in 2025 and over the long term. The healthcare space is a great place to look for these sorts of players because here you'll find all that you need to gain in both growth and security -- from young biotechs developing game-changing technologies to big pharma or medical device p...

Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that investing in the right stock at the right time -- and holding onto it for a while -- is one of the best formulas for earning terrific returns.

Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all climbed by double digits. Investor enthusiasm about technology and growth stocks, and the economic environment ahead, drove the momentum.

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic partnership with Vertex Pharmaceuticals has provided stability and resources, leading to the first FDA-approved CRISPR-based gene editing treatment, Casgevy. Editas' discontinuation of its SCD and TDT pr...

CRISPR Therapeutics AG (NASDAQ:CRSP ) 43rd Annual JPMorgan Healthcare Conference Call January 14, 2025 5:15 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer and Chairman Conference Call Participants Fanchen Zhou - JPMorgan Fanchen Zhou Good afternoon, everyone. Thank you for coming here.

If you're an investor searching for the next big market winners, Wall Street analysts have zeroed in on one biotech stock that could deliver huge gains in a defined time frame.

Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more modest valuations. Mid-cap stocks represent companies valued at between $2 billion and $10 billion.